Researchers at Imperial College London have designed a microchip technology that they say may help curb the obesity problem in developed nations. The chip, which presently is being tested in animals, is implanted in the gut, where it sends satiation signals to the brain. The researchers project that they will begin tests in patients in three to four years.

Of mice and men. A team from the Cleveland Clinic used animal and human studies to accumulate evidence that challenges conventional wisdom on red meat and cardiovascular disease. Red meat is still on the hook, but the culprit appears to be a byproduct of bacteria involved in the digestion of red meat. The New York Times describes the multiyear effort, including results published in Nature Medicine.

Cholesterol may play a role in the development of macular degeneration, according to a study published online in Cell Metabolism.

The Children's Hospital of Philadelphia (CHOP) and Pfizer, Inc., are joining forces with the goal of translating biomedical discoveries into novel treatments. CHOP is announcing its participation in the Centers for Therapeutic Innovation (CTI) network, a novel collaboration model built by Pfizer that brings academic researchers together with Pfizer scientists to expedite the pace of innovation.

The Republic of San Marino, which is known among philatelists for its postal offerings, plans to release a stamp April 3 designed to raise awareness of cardiovascular disease.

Medtronic, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and the first U.S. clinical uses of its new Affinity Fusion oxygenation system.

U.S. adolescents’ lack of heart-healthy behaviors may increase their chances of heart disease as adults.

Martyn Thomas, MD, director of cardiothoracic services, Guys and St. Thomas' NHS Foundation Trust in London, reported Tuesday on the one-year mortality rates with transcatheter heart valve implantations with the Sapien valve (Edwards Lifesciences) using either a transfemoral or transapical approach, based on results of 1,038 high-risk patients assessed in the SOURCE Registry at EuroPCR in Paris. Slides